Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA
NRG Oncology
NRG Oncology
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Bristol-Myers Squibb
Daiichi Sankyo
BicycleTx Limited
Fudan University
Alliance for Clinical Trials in Oncology
Hutchmed
University Health Network, Toronto
Sutro Biopharma, Inc.
SWOG Cancer Research Network
Tata Memorial Centre
Amsterdam UMC, location VUmc
Vasgene Therapeutics, Inc
Gruppo Oncologico del Nord-Ovest
Universität des Saarlandes
Tyme, Inc
Panbela Therapeutics, Inc.
1Globe Biomedical Co., Ltd.
Fudan University
Qilu Pharmaceutical Co., Ltd.
EMD Serono
National Cancer Institute, Naples
National Cancer Centre, Singapore
ERYtech Pharma
Delcath Systems Inc.
Sun Yat-sen University
CG Oncology, Inc.
AB Science
Krankenhaus Nordwest
Lumos Pharma
Celgene
Tianjin Medical University Cancer Institute and Hospital
The Clatterbridge Cancer Centre NHS Foundation Trust
Guangxi Medical University
Guangxi Medical University
Celgene
Guangdong Association of Clinical Trials
Shandong Cancer Hospital and Institute
Merrimack Pharmaceuticals
Transgene
Federation Francophone de Cancerologie Digestive
Bristol-Myers Squibb
Tianjin Medical University Cancer Institute and Hospital
CONKO-Studiengruppe
University College, London
Sun Yat-sen University
European Organisation for Research and Treatment of Cancer - EORTC
IRCCS San Raffaele